Skip to main content
The BMJ logoLink to The BMJ
. 1992 Feb 22;304(6825):471–473. doi: 10.1136/bmj.304.6825.471

Motor neurone disease: a hospice perspective.

T O'Brien 1, M Kelly 1, C Saunders 1
PMCID: PMC1881117  PMID: 1547416

Abstract

OBJECTIVE--To describe and evaluate the management of patients with motor neurone disease from the perspective of a hospice. DESIGN--Retrospective analysis of hospice medical and nursing notes. SETTING--Established 62 bed teaching and research hospice. SUBJECTS--124 patients with motor neurone disease cared for by the hospice between January 1980 and November 1990. MAIN OUTCOME MEASURES--Patient profile; functional status; symptom control and use of opioids; insight; mode and management of death. RESULTS--124 patients (67 women, 57 men) had a mean age 63.9 years. The median length of admission was 61.5 days (range 1 to 2147). 84 patients (68%) were aware of their diagnosis and its implications when first seen by a hospice doctor. Functionally, the patients were very dependent. Symptoms such as pain, dyspnoea, and insomnia were major problems that responded well to opioids. Many patients were noted to deteriorate "suddenly," and in 58% of cases death occurred within 24 hours of this deterioration. When dying, 106 patients (94%) were peaceful and settled. 101 patients (89%) received opioids during this dying period. No patient chocked to death. CONCLUSIONS--Although motor neurone disease is an uncommon disorder, many of its symptoms occur commonly in medical practice and must be actively treated. Opioids are both safe and effective for such treatment. The term chocking is both inaccurate and inappropriate in describing the cause of death in motor neurone disease and its use should be abandoned.

Full text

PDF
471

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Hillel A. D., Miller R. M. Management of bulbar symptoms in amyotrophic lateral sclerosis. Adv Exp Med Biol. 1987;209:201–221. doi: 10.1007/978-1-4684-5302-7_32. [DOI] [PubMed] [Google Scholar]
  2. Howard R. S., Wiles C. M., Loh L. Respiratory complications and their management in motor neuron disease. Brain. 1989 Oct;112(Pt 5):1155–1170. doi: 10.1093/brain/112.5.1155. [DOI] [PubMed] [Google Scholar]
  3. Mulder D. W., Howard F. M., Jr Patient resistance and prognosis in amyotrophic lateral sclerosis. Mayo Clin Proc. 1976 Sep;51(9):537–541. [PubMed] [Google Scholar]
  4. Mulder D. W., Kurland L. T. Motor neuron disease: epidemiologic studies. Adv Exp Med Biol. 1987;209:325–332. doi: 10.1007/978-1-4684-5302-7_49. [DOI] [PubMed] [Google Scholar]
  5. Newrick P. G., Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry. 1985 Aug;48(8):838–840. doi: 10.1136/jnnp.48.8.838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Norris F. H., Denys E. H., Sang K., Mukai E. [The natural history of ALS in a specified population, with comments on risk factors, prognosis and symptomatic treatments]. Rinsho Shinkeigaku. 1989 Dec;29(12):1485–1492. [PubMed] [Google Scholar]
  7. Norris F. H., Smith R. A., Denys E. H. Motor neurone disease: towards better care. Br Med J (Clin Res Ed) 1985 Jul 27;291(6490):259–262. doi: 10.1136/bmj.291.6490.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rose F. C. The management of motor neurone disease. Adv Exp Med Biol. 1987;209:167–174. doi: 10.1007/978-1-4684-5302-7_28. [DOI] [PubMed] [Google Scholar]
  9. Rosin A. J. The problems of motor neurone disease. Age Ageing. 1976 Feb;5(1):37–42. doi: 10.1093/ageing/5.1.37. [DOI] [PubMed] [Google Scholar]
  10. Schiffer D., Brignolio F., Chió A., Leone M., Rosso M. G. A study of prognostic factors in motor neuron disease. Adv Exp Med Biol. 1987;209:255–263. doi: 10.1007/978-1-4684-5302-7_37. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES